RT Journal Article
SR Electronic
T1 Declining Course of Humoral Immune Response in Initially Responding Kidney Transplant Recipients after Repeated SARS-CoV-2 Vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.29.22272858
DO 10.1101/2022.03.29.22272858
A1 Ronicke, Simon
A1 Osmanodja, Bilgin
A1 Budde, Klemens
A1 Jens, Annika
A1 Hammett, Charlotte
A1 Koch, Nadine
A1 Zukunft, Bianca
A1 Bachmann, Friederike
A1 Choi, Mira
A1 Weber, Ulrike
A1 Eberspächer, Bettina
A1 Hofmann, Jörg
A1 Grunow, Fritz
A1 Mikhailov, Michael
A1 Halleck, Fabian
A1 Schrezenmeier, Eva
YR 2022
UL http://medrxiv.org/content/early/2022/04/02/2022.03.29.22272858.abstract
AB Immunogenicity of SARS-CoV-2 vaccines in kidney transplant recipients is limited, resulting in inadequately low serological response rates and low immunoglobulin (Ig) levels, correlating with reduced protection against death and hospitalization from COVID-19. We retrospectively examined the time course of anti-SARS-CoV-2 Ig antibody levels after up to five repeated vaccinations in 644 previously nonresponding kidney transplant recipients. Using anti SARS-CoV-2 IgG/IgA ELISA and the total Ig ECLIA assays, we compare antibody levels at 1 month with levels at 2 and 4 months, respectively. Additionally, we correlate the measurements of the used assays.Between 1 and 2 months, and between 1 and 4 months, mean anti-SARS-CoV-2 Ig levels in responders decreased by 14% and 25%, respectively, depending on the assay. Absolute Ig values and time course of antibody levels and showed high interindividual variability. Ig levels decreased by at least 20% in 77 of 148 paired samples with loss of sufficient serological protection over time occurring in 18 out of 148 (12.2%).IgG ELISA and total Ig ECLIA assays showed a strong positive correlation (Kendall’s tau=0.78), yet the two assays determined divergent results in 99 of 751 (13.2%) measurements. IgG and IgA assays showed overall strong correlation but divergent results in 270 of 1.173 (23.0%) cases and only weak correlation of antibody levels in positive samples.Large interindividual variability and significant loss of serological protection after 4 months supports repeated serological sampling and consideration of shorter vaccination intervals in kidney transplant recipients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:institutional ethics committee of Charite - Universitaetsmedizin Berlin, Berlin, Germany, ethics votum EA1/030/22I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this study are available on request from the corresponding author. The data are not publicly available due to their containing personal information that could compromise the privacy of involved patients.